Of note, trials assessing the efficacy of several PTPN1 inhibitors for the treatment of type 2 diabetes were halted due to low efficacy and toxicities, including vomiting and diarrhoea [127,128]. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.